Publication Information

{'id': 'https://openalex.org/W3032515387', 'doi': None, 'title': 'Zanubrutinib Appears to be Safe, Effective for Waldenström Macroglobulinemia', 'display_name': 'Zanubrutinib Appears to be Safe, Effective for Waldenström Macroglobulinemia', 'publication_year': 2020, 'publication_date': '2020-05-29', 'ids': {'openalex': 'https://openalex.org/W3032515387', 'mag': '3032515387'}, 'language': 'en', 'primary_location': {'is_oa': False, 'landing_page_url': 'https://www.cancernetwork.com/asco-hematology/zanubrutinib-appears-be-safe-effective-waldenstrm-macroglobulinemia', 'pdf_url': None, 'source': None, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}, 'type': 'article', 'type_crossref': 'journal-article', 'indexed_in': [], 'open_access': {'is_oa': False, 'oa_status': 'closed', 'oa_url': None, 'any_repository_has_fulltext': False}, 'authorships': [{'author_position': 'first', 'author': {'id': 'https://openalex.org/A5024251953', 'display_name': 'Brielle Benyon', 'orcid': None}, 'institutions': [], 'countries': [], 'is_corresponding': True, 'raw_author_name': 'Brielle Benyon', 'raw_affiliation_strings': [], 'affiliations': []}], 'institution_assertions': [], 'countries_distinct_count': 0, 'institutions_distinct_count': 0, 'corresponding_author_ids': ['https://openalex.org/A5024251953'], 'corresponding_institution_ids': [], 'apc_list': None, 'apc_paid': None, 'fwci': 0.0, 'has_fulltext': False, 'cited_by_count': 0, 'citation_normalized_percentile': {'value': 0.0, 'is_in_top_1_percent': False, 'is_in_top_10_percent': False}, 'cited_by_percentile_year': {'min': 0, 'max': 60}, 'biblio': {'volume': None, 'issue': None, 'first_page': None, 'last_page': None}, 'is_retracted': False, 'is_paratext': False, 'primary_topic': {'id': 'https://openalex.org/T11157', 'display_name': 'Chronic Lymphocytic Leukemia Research', 'score': 0.9995, 'subfield': {'id': 'https://openalex.org/subfields/2716', 'display_name': 'Genetics'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, 'topics': [{'id': 'https://openalex.org/T11157', 'display_name': 'Chronic Lymphocytic Leukemia Research', 'score': 0.9995, 'subfield': {'id': 'https://openalex.org/subfields/2716', 'display_name': 'Genetics'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}], 'keywords': [{'id': 'https://openalex.org/keywords/macroglobulinemia', 'display_name': 'Macroglobulinemia', 'score': 0.7441639}, {'id': 'https://openalex.org/keywords/tolerability', 'display_name': 'Tolerability', 'score': 0.7204578}], 'concepts': [{'id': 'https://openalex.org/C2779878957', 'wikidata': 'https://www.wikidata.org/wiki/Q5984881', 'display_name': 'Ibrutinib', 'level': 4, 'score': 0.98232996}, {'id': 'https://openalex.org/C2781038049', 'wikidata': 'https://www.wikidata.org/wiki/Q1778287', 'display_name': 'Waldenstrom macroglobulinemia', 'level': 3, 'score': 0.84114885}, {'id': 'https://openalex.org/C2776391228', 'wikidata': 'https://www.wikidata.org/wiki/Q4118092', 'display_name': 'Macroglobulinemia', 'level': 3, 'score': 0.7441639}, {'id': 'https://openalex.org/C2778375690', 'wikidata': 'https://www.wikidata.org/wiki/Q7814214', 'display_name': 'Tolerability', 'level': 3, 'score': 0.7204578}, {'id': 'https://openalex.org/C71924100', 'wikidata': 'https://www.wikidata.org/wiki/Q11190', 'display_name': 'Medicine', 'level': 0, 'score': 0.57713485}, {'id': 'https://openalex.org/C90059517', 'wikidata': 'https://www.wikidata.org/wiki/Q423572', 'display_name': "Bruton's tyrosine kinase", 'level': 4, 'score': 0.5727286}, {'id': 'https://openalex.org/C143998085', 'wikidata': 'https://www.wikidata.org/wiki/Q162555', 'display_name': 'Oncology', 'level': 1, 'score': 0.3716209}, {'id': 'https://openalex.org/C126322002', 'wikidata': 'https://www.wikidata.org/wiki/Q11180', 'display_name': 'Internal medicine', 'level': 1, 'score': 0.3686878}, {'id': 'https://openalex.org/C197934379', 'wikidata': 'https://www.wikidata.org/wiki/Q2047938', 'display_name': 'Adverse effect', 'level': 2, 'score': 0.22040632}, {'id': 'https://openalex.org/C2779338263', 'wikidata': 'https://www.wikidata.org/wiki/Q208414', 'display_name': 'Lymphoma', 'level': 2, 'score': 0.16935542}, {'id': 'https://openalex.org/C2777938653', 'wikidata': 'https://www.wikidata.org/wiki/Q1088156', 'display_name': 'Chronic lymphocytic leukemia', 'level': 3, 'score': 0.13503298}, {'id': 'https://openalex.org/C2778461978', 'wikidata': 'https://www.wikidata.org/wiki/Q29496', 'display_name': 'Leukemia', 'level': 2, 'score': 0.115182936}, {'id': 'https://openalex.org/C42362537', 'wikidata': 'https://www.wikidata.org/wiki/Q87099740', 'display_name': 'Tyrosine kinase', 'level': 3, 'score': 0.087163925}, {'id': 'https://openalex.org/C170493617', 'wikidata': 'https://www.wikidata.org/wiki/Q208467', 'display_name': 'Receptor', 'level': 2, 'score': 0.078436166}, {'id': 'https://openalex.org/C2776364478', 'wikidata': 'https://www.wikidata.org/wiki/Q467635', 'display_name': 'Multiple myeloma', 'level': 2, 'score': 0.0}], 'mesh': [], 'locations_count': 1, 'locations': [{'is_oa': False, 'landing_page_url': 'https://www.cancernetwork.com/asco-hematology/zanubrutinib-appears-be-safe-effective-waldenstrm-macroglobulinemia', 'pdf_url': None, 'source': None, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}], 'best_oa_location': None, 'sustainable_development_goals': [], 'grants': [], 'datasets': [], 'versions': [], 'referenced_works_count': 0, 'referenced_works': [], 'related_works': ['https://openalex.org/W3178605716', 'https://openalex.org/W3172476833', 'https://openalex.org/W3168105394', 'https://openalex.org/W3097324094', 'https://openalex.org/W2953303695', 'https://openalex.org/W2952004740', 'https://openalex.org/W2951924370', 'https://openalex.org/W2951773279', 'https://openalex.org/W2936133946', 'https://openalex.org/W2889637655', 'https://openalex.org/W2807517936', 'https://openalex.org/W2566930362', 'https://openalex.org/W2510982931', 'https://openalex.org/W2281700801', 'https://openalex.org/W2103859686', 'https://openalex.org/W2091412133', 'https://openalex.org/W2088018231', 'https://openalex.org/W2064083690', 'https://openalex.org/W1986198519', 'https://openalex.org/W1486606013'], 'abstract_inverted_index': {'According': [0], 'to': [1, 17, 40], 'the': [2], 'largest': [3], 'phase': [4], 'III': [5], 'trial': [6], 'examining': [7], 'BTK': [8], 'inhibitors': [9], 'for': [10], 'patients': [11], 'with': [12, 20], 'Waldenstrom': [13], 'macroglobulinemia,': [14], 'zanubrutinib': [15], 'appears': [16], 'be': [18], 'associated': [19], 'higher': [21], 'complete': [22], 'response': [23], 'or': [24], 'very': [25], 'good': [26], 'partial': [27], 'response,': [28], 'as': [29, 31], 'well': [30], 'clinically': [32], 'meaningful': [33], 'advantages': [34], 'in': [35], 'safety': [36], 'and': [37], 'tolerability': [38], 'compared': [39], 'ibrutinib.': [41]}, 'cited_by_api_url': 'https://api.openalex.org/works?filter=cites:W3032515387', 'counts_by_year': [], 'updated_date': '2024-12-30T21:58:50.755175', 'created_date': '2020-06-05'}